Chenan Zhang

Chenan Zhang

Auto-generated profile, based on publicly available information

Chenan Zhang

Department of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, California

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 September 2020 in Science
Verified
Journal Article
Closed access
KDKathryn Demanelis
Kathryn Demanelis
FJFarzana Jasmine
Farzana Jasmine
LCLin S. Chen
Lin S. Chen
MCMeytal Chernoff
Meytal Chernoff
LTLin Tong
Lin Tong
BPBrandon L. Pierce
Brandon L. Pierce
Telomere length within an individual varies in a correlated manner across most tissues.

1 January 2020 in Bone
Verified
Journal Article
Closed access
CZChenan Zhang
Chenan Zhang
HHHelen M. Hansen
Helen M. Hansen
ESEleanor C. Semmes
Eleanor C. Semmes
JGJulio Gonzalez-Maya
Julio Gonzalez-Maya
LMLibby Morimoto
Libby Morimoto
KWKyle M. Walsh
Kyle M. Walsh

28 May 2020 in Cancer Epidemiology, Biomarkers & Prevention
Verified
Journal Article
Open access
PDF file
ESEleanor C. Semmes
Eleanor C. Semmes
JVJayaram Vijayakrishnan
Jayaram Vijayakrishnan
CZChenan Zhang
Chenan Zhang
JHJillian H. Hurst
Jillian H. Hurst
Richard HoulstonRichard Houlston
Richard Houlston
KWKyle M. Walsh
Kyle M. Walsh
Background: Genome-wide association studies (GWAS) of childhood cancers remain limited, highlighting the need for novel analytic strategies. We describe a hybrid GWAS and phenome-wide association study (PheWAS) approach to uncover genotype–phenotype relationships and candidate risk loci, applying it to acute lymphoblastic leukemia (ALL). Methods: PheWAS was performed for 12 ALL SNPs identified by prior GWAS and two control SNP-sets using UK Biobank data. PheWAS-traits significantly associated with ALL SNPs compared with control SNPs were assessed for association with ALL risk (959 cases, 2,624 controls) using polygenic score and Mendelian randomization analyses. Trait-associated SNPs were tested for association with ALL risk in single-SNP analyses, with replication in an independent case–control dataset (1,618 cases, 9,409 controls). Results: Platelet count was the trait most enriched for association with known ALL risk loci. A polygenic score for platelet count (223 SNPs) was not associated with ALL risk (P = 0.82) and Mendelian randomization did not suggest a causal relationship. However, twelve platelet count-associated SNPs were nominally associated with ALL risk in COG data and three were replicated in UK data (rs10058074, rs210142, rs2836441). Conclusions: In our hybrid GWAS–PheWAS approach, we identify pleiotropic genetic variation contributing to ALL risk and platelet count. Three SNPs known to influence platelet count were reproducibly associated with ALL risk, implicating genomic regions containing IRF1, proapoptotic protein BAK1, and ERG in platelet production and leukemogenesis. Impact: Incorporating PheWAS data into association studies can leverage genetic pleiotropy to identify cancer risk loci, highlighting the utility of our novel approach.

3 October 2018 in International Journal of Cancer
Verified
Journal Article
Closed access
PDF file
ASAdam de Smith
Adam de Smith
KWKyle M. Walsh
Kyle M. Walsh
SFStephen S. Francis
Stephen S. Francis
CZChenan Zhang
Chenan Zhang
HHHelen M. Hansen
Helen M. Hansen
JWJoseph L. Wiemels
Joseph L. Wiemels

15 September 2018 in Cancer
Verified
Journal Article
Closed access
PDF file
CZChenan Zhang
Chenan Zhang
LMLibby M. Morimoto
Libby M. Morimoto
ASAdam J. de Smith
Adam J. de Smith
HHHelen M. Hansen
Helen M. Hansen
JGJulio Gonzalez‐Maya
Julio Gonzalez‐Maya
KWKyle M. Walsh
Kyle M. Walsh

12 February 2022 in Current Oncology
Verified
Journal Article
Open access
PDF file
JLJeanna Law
Jeanna Law
DMDebanjali Mitra
Debanjali Mitra
HKHenry G Kaplan
Henry G Kaplan
TATamuno Alfred
Tamuno Alfred
ABAdam Brufsky
Adam Brufsky
CCConnie Chen
Connie Chen
This retrospective single-arm study assessed real-world treatment patterns and clinical outcomes in patients with hormone receptor—positive/human epidermal growth factor receptor 2—negative (HR+/HER2−) advanced/metastatic breast cancer (A/MBC) who received palbociclib plus an aromatase inhibitor as first-line therapy in US community health systems. Using electronic health records from the Syapse Learning Health Network, 242 patients were identified as having received first-line palbociclib plus an aromatase inhibitor between 3 February 2015, and 31 July 2019 (data cutoff 1 February 2020) resulting in a minimum potential 6-month follow-up period. In total, 56.6% of patients had de novo A/MBC at initial breast cancer diagnosis, 50.8% had bone-only disease, and 32.2% had visceral disease. Median follow-up was 22.4 months. Disease progression (26.4%) and intolerance/toxicity (14.9%) were the main reasons for treatment discontinuation. The median (95% CI) real-world progression-free survival was 31.7 (27.9—not estimable (NE)) months and 2-year estimated overall survival (OS) rate was 78.0%. In total, 25.6% of patients died; however, OS data are limited by the small population size and insufficient follow-up time. These real-world effectiveness outcomes complement findings from other real-world studies and randomized controlled trials and support palbociclib plus an aromatase inhibitor as first-line therapy for HR+/HER2− A/MBC.